Clinical analysis of chronic hepatitis B with concurrent hepatitis e antigen and antibody during antiviral therapy / 实用医学杂志
The Journal of Practical Medicine
;
(24): 1778-1780, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-467615
ABSTRACT
Objective To evaluate the clinical significance of chronic hepatitis B (CHB) with concurrent hepatitis e antigen (HBeAg) and antibody (anti-HBe) during antiviral therapy. Methods A total of 115 CHB patients with concurrent HBeAg and anti-Hbe detection during antiviral therapy were enrolled in this retrospective study. All patients received pegylated-IFN-alpha-2a (Peg-IFNα-2a, n = 50) or entecavir (ETV, n = 65) for antiviral treatment. Their biochemical virological and serological response and clinical outcome were detected and analyzed. Results Among the patients treated with Peg-IFNα-2a, 31 (62.0%) achieved HBeAg seroconversion and 6 (12.0%) achieved HBsAg seroconversion at the end of treatment. About 35.4% of patients, who received ETV, achieved HBeAg seroconversion and none of them achieved HBsAg seroconversion at the end of treatment (P < 0.05). Conclusion High rates of HBeAg seroconversion and HBsAg loss could be achieved in CHB patients, with co-existence of HBeAg and anti-HBe, who received Peg-IFNα-2a, but not ETV therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Observational study
Language:
Chinese
Journal:
The Journal of Practical Medicine
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS